Efficacy and Safety of PVT-1 Treatment in Patients With Advanced and Refractory Non-Small Cell Lung Cancer
Latest Information Update: 10 Apr 2023
At a glance
- Drugs Aprepitant (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors PlusVitech
- 04 Apr 2023 Planned End Date changed from 15 Dec 2022 to 31 Dec 2025.
- 04 Apr 2023 Planned primary completion date changed from 15 Dec 2022 to 31 Dec 2025.
- 03 May 2022 Planned End Date changed from 15 Dec 2021 to 15 Dec 2022.